Cytek Biosciences

Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cytek Biosciences reports robust earnings, eyes growth through acquisitions

Cytek Biosciences delivered strong financial results in Q4 2022 and full year 2022, driven by revenue growth, strategic partnerships, and acquisitions.
The company's focus on revenue diversification, technological enhancements, and operational efficiencies positions it for continued growth and innovation in 2023.
While facing integration and operational challenges, Cytek remains optimistic about revenue growth, market expansion, and service margin improvements in the coming year.

Cytek Biosciences reports mixed Q1 results, eyes strategic growth

Cytek Biosciences saw mixed Q1 performance with revenue growth from acquisitions but organic revenue decline.
Strategic partnerships and product launches are strengthening Cytek's position in the market.
Challenges in revenue growth and increased expenses highlight the need for operational efficiency.
Despite financial setbacks, Cytek remains optimistic about future growth opportunities and market leadership.

Cytek Biosciences reports strong Q2 earnings, eyes growth opportunities

Cytek Biosciences delivered a robust performance in Q2 2023, marked by strong revenue growth and operational efficiency despite increased expenses.
The company's strategic focus on driving growth through acquisitions, technology advancements, and market opportunities bodes well for future expansion.
While challenges in managing expenses persist, Cytek's solid financial position and confidence in addressing market needs position it for sustained growth.
With a clear roadmap for growth and a talented team, Cytek remains poised to capitalize on opportunities and enhance shareholder value.

Cytek Biosciences reports solid Q3 growth and eyes global expansion

Cytek Biosciences delivered strong Q3 results with revenue growth and strategic focus on key pillars.
Despite challenges in sales cycles and order delays, the company remains innovative and responsive in the market.
Opportunities in new product launches, bioinformatics, and clinical markets provide avenues for future growth.
Cytek's performance reflects resilience amidst industry challenges and a commitment to driving innovation and expansion.

Cytek Biosciences reports robust Q4 earnings, eyes growth opportunities

Cytek Biosciences delivered strong financial results in Q4 2023, driven by revenue growth and operational efficiency, with a focus on profitability and innovation.
The company faces challenges in managing expenses, stabilizing revenue in key markets, and balancing new product contributions with cost control measures.
Opportunities lie in capitalizing on revenue outlook, expanding in the biotech segment, leveraging regional growth, and diversifying revenue streams.
Strategic planning and execution will be crucial for Cytek Biosciences to navigate challenges and maximize opportunities for sustainable growth and market leadership.

Cytek Biosciences reports strong Q1 growth amidst global market expansion

Cytek Biosciences' Q1 2024 performance reflects solid revenue growth and market expansion efforts.
While facing challenges in certain regions, the company is leveraging opportunities in product innovation and global demand.
Maintaining financial discipline and focusing on operational efficiency will be key to achieving profitability and sustained growth.

Cytek Biosciences reports Q2 revenue growth, eyes global expansion

Cytek Biosciences showed mixed performance in Q2 2024 with revenue growth in EMEA and APAC but a decline in the U.S., particularly in academic and government sectors.
The company's focus on key growth pillars and new capabilities like the ESP module, along with strategic initiatives like Cytek Cloud, positions it for future growth.
While facing challenges in the U.S. market, Cytek Biosciences aims to drive sustainable growth and profitability through cost control and revenue enhancement strategies.

Cytek Biosciences reports strong Q3 earnings, eyes global expansion

Cytek Biosciences demonstrated solid financial performance in Q3 2024, driven by revenue growth and effective expense management.
The company's strategic focus on key pillars and expanding user base positions it well for future success and market leadership.
While facing challenges in balancing investments and income, Cytek has opportunities to capitalize on global growth and market trends.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.

Boeing

JAKKS Pacific

MGM Resorts

US stocks closed mixed on Wednesday following the release of minutes from the recent Federal Reserve meeting. Investors, meanwhile, focused on some notable insider trades.

Boeing And 3 Other Stocks Bought By Insiders

FREMONT, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating virtually in the upcoming 42nd Annual Cowen Health Care Conference.

Cytek to Participate in the 42nd Annual Cowen Health Care Conference

FREMONT, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23rd, 2022. The company's management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

Operations to Accommodate Increasing Demand for Cell Analysis Solutions Operations to Accommodate Increasing Demand for Cell Analysis Solutions

Cytek® Biosciences Expands Fremont Headquarters, Tripling Its Manufacturing Capacity

Cytek Biosciences, Inc. (CTKB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Cytek Biosciences, Inc. (CTKB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Company Continues Forward Momentum Following IPO, Expanded Product Portfolio and Increased Global Footprint Company Continues Forward Momentum Following IPO, Expanded Product Portfolio and Increased Global Footprint

Cytek® Biosciences Marks Milestone Achievement with Shipment of 1000th Cell Analysis System

Cytek Biosciences, Inc.'s (CTKB) CEO Wenbin Jiang on Q3 2021 Results - Earnings Call Transcript

Third quarter total revenue growth of 37% compared to prior year Third quarter total revenue growth of 37% compared to prior year

Cytek Biosciences Reports Third Quarter 2021 Financial Results

FREMONT, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has acquired the cell analysis business of Tonbo Biosciences™, which includes an extensive portfolio of life science research reagents related to cell preparation, flow cytometry, molecular immunology/PCR and cell culture covering application areas across immunology, apoptosis, and immunoprofiling.

Cytek Biosciences Acquires Tonbo Biosciences' Cell Analysis Business

FREMONT, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8th, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report Third Quarter Financial Results on November 8, 2021

Optimized for Cytek Aurora Cell Analysis Systems; Delivers Turnkey Solution for Immunophenotyping Optimized for Cytek Aurora Cell Analysis Systems; Delivers Turnkey Solution for Immunophenotyping

Cytek® Biosciences Introduces New 25-Color Immunoprofiling Assay

FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021.

Cytek Biosciences Reports Second Quarter 2021 Financial Results

FREMONT, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that the underwriters of its previously announced initial public offering, which closed on July 27, 2021, have exercised in full their option to purchase 2,184,695 additional shares of common stock at the price to the public of $17.00 per share. With the addition of the full exercise of the underwriters' option to purchase additional shares, the total number of shares sold in this offering increased to 16,749,330, and the aggregate gross proceeds to Cytek, before deducting underwriting discounts and commissions and estimated offering expenses, were $237 million. The offering consisted of 13,949,401 shares issued and sold by Cytek, and 2,799,929 shares sold by the selling stockholders named in the prospectus. Cytek did not receive any proceeds from the sale of shares by the selling stockholders.

Cytek Biosciences Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

FREMONT, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the closing of its initial public offering of an aggregate of 14,564,635 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Cytek from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were $200 million. The offering consisted of 11,764,706 shares issued and sold by Cytek, and 2,799,929 shares sold by the selling stockholders named in the prospectus. Cytek did not receive any proceeds from the sale of shares by the selling stockholders. In addition, Cytek has granted the underwriters a 30-day option to purchase up to an additional 2,184,695 shares of common stock solely to cover over-allotments, if any, at the initial public offering price, less underwriting discounts and commissions. Cytek's shares of common stock are listed for trading on The Nasdaq Global Select Market under the ticker symbol “CTKB”.

Cytek Biosciences Announces Closing of Its Initial Public Offering

Cytek Biosciences has filed to raise $248 million in an IPO.

Cytek Biosciences Proposes Terms For $248 Million IPO

Cytek Biosciences, Inc. is going public on July 22, 2021. The addressable market is going to rise with a CAGR of 7.2-15% for the next few years.

News for Cytek Biosciences Stock (CTKB)